Alnylam Grants Qiagen License to Kreutzer-Limmer Patents
News Sep 22, 2005
Alnylam Pharmaceuticals, Inc. has announced that it has granted Qiagen N.V. a non-exclusive license to provide research products and services in RNA interference under the Kreutzer-Limmer patent family.
This patent family, owned by Alnylam, covers small interfering RNAs and their use to mediate RNAi in mammalian cells.
"We are very pleased to announce that Qiagen has taken a license to Alnylam's Kreutzer-Limmer patent family," said Vincent Miles, Ph.D., Senior Vice President, Business Development of Alnylam Pharmaceuticals.
"Because Qiagen already has one of the four co-exclusive licenses for research products under the 'Tuschl' patent applications, this agreement emphasizes the importance of the Kreutzer-Limmer patent family for any commercialization of siRNAs."
"Alnylam intends to continue leveraging its leading intellectual property estate through partnerships that create value."
"Qiagen is a leading supplier of siRNA libraries and high throughput siRNA synthesis technology," said Dr. Ulrich Schriek, Qiagen's Vice President Corporate Business Development.
"This license agreement with Alnylam further strengthens Qiagen’s position as a key licensed supplier of siRNAs to the scientific community."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.